JP7378847B2 - スフィンゴモナス属細菌由来のナノ小胞及びその用途 - Google Patents
スフィンゴモナス属細菌由来のナノ小胞及びその用途 Download PDFInfo
- Publication number
- JP7378847B2 JP7378847B2 JP2022078846A JP2022078846A JP7378847B2 JP 7378847 B2 JP7378847 B2 JP 7378847B2 JP 2022078846 A JP2022078846 A JP 2022078846A JP 2022078846 A JP2022078846 A JP 2022078846A JP 7378847 B2 JP7378847 B2 JP 7378847B2
- Authority
- JP
- Japan
- Prior art keywords
- sphingomonas
- vesicles
- bacteria
- derived
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000736131 Sphingomonas Species 0.000 title claims description 87
- 241000894006 Bacteria Species 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 50
- 241000736110 Sphingomonas paucimobilis Species 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 241000834608 Sphingomonas bacterium Species 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 241000344853 Sphingomonas koreensis Species 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 description 51
- 239000008280 blood Substances 0.000 description 51
- 206010012438 Dermatitis atopic Diseases 0.000 description 48
- 201000008937 atopic dermatitis Diseases 0.000 description 48
- 208000010877 cognitive disease Diseases 0.000 description 38
- 208000001647 Renal Insufficiency Diseases 0.000 description 36
- 206010012601 diabetes mellitus Diseases 0.000 description 36
- 201000010099 disease Diseases 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 201000006370 kidney failure Diseases 0.000 description 36
- 208000003174 Brain Neoplasms Diseases 0.000 description 35
- 238000000034 method Methods 0.000 description 35
- 208000027061 mild cognitive impairment Diseases 0.000 description 35
- 208000010125 myocardial infarction Diseases 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 34
- 208000019425 cirrhosis of liver Diseases 0.000 description 34
- 201000007270 liver cancer Diseases 0.000 description 34
- 208000014018 liver neoplasm Diseases 0.000 description 34
- 206010003805 Autism Diseases 0.000 description 32
- 208000020706 Autistic disease Diseases 0.000 description 32
- 238000009826 distribution Methods 0.000 description 30
- 206010012289 Dementia Diseases 0.000 description 29
- 230000001580 bacterial effect Effects 0.000 description 25
- 230000028327 secretion Effects 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000002757 inflammatory effect Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 230000001717 pathogenic effect Effects 0.000 description 11
- 239000006210 lotion Substances 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 208000014644 Brain disease Diseases 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- -1 etc. Chemical class 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000108056 Monas Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000030429 T-helper 17 type immune response Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- WVCHIGAIXREVNS-UHFFFAOYSA-N 2-hydroxy-1,4-naphthoquinone Chemical compound C1=CC=C2C(O)=CC(=O)C(=O)C2=C1 WVCHIGAIXREVNS-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000011514 Familial renal glucosuria Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- 229960001063 cinoxate Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 1
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- MCPKSFINULVDNX-UHFFFAOYSA-N drometrizole Chemical compound CC1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 MCPKSFINULVDNX-UHFFFAOYSA-N 0.000 description 1
- 229960000979 drometrizole Drugs 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- CSFWPUWCSPOLJW-UHFFFAOYSA-N hydroxynaphthoquinone Natural products C1=CC=C2C(=O)C(O)=CC(=O)C2=C1 CSFWPUWCSPOLJW-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 description 1
- 229960002248 meradimate Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 208000007278 renal glycosuria Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
Description
(a)健常者及び被検者のサンプルから分離した小胞からDNAを抽出する段階と、
(b)前記抽出したDNAに対して16S rDNAに存在する遺伝子の配列に基づいて作製したプライマーペアを用いてPCRを行った後、それぞれのPCR産物を得る段階と、
(c)前記PCR産物の定量分析を通じて健常者に比べてスフィンゴモナス属細菌由来の小胞の含量が低い場合、肝硬変、肝がん、心筋梗塞、腎不全、糖尿病、脳腫瘍、軽度認知障害、認知症、うつ病、自閉症、及びアトピー性皮膚炎からなる群から選ばれた一つ以上の疾患であると判定する段階。
(a)健常者及び被検者のサンプルから分離した小胞からDNAを抽出する段階と、
(b)前記抽出したDNAに対して16S rDNAに存在する遺伝子の配列に基づいて作製したプライマーペアを用いてPCRを行った後、それぞれのPCR産物を得る段階と、
(c)前記PCR産物の定量分析を通じて健常者に比べてスフィンゴモナス属細菌由来の小胞の含量が低い場合、肝硬変、肝がん、心筋梗塞、腎不全、糖尿病、脳腫瘍、軽度認知障害、認知症、うつ病、自閉症、及びアトピー性皮膚炎からなる群から選ばれた一つ以上の疾患であると判定する段階。
(a)健常者及び被検者のサンプルから分離した小胞からDNAを抽出する段階と、
(b)前記抽出したDNAに対して16S rDNA塩基配列に基づいて作製したプライマーペアを用いてPCRを行った後、それぞれのPCR産物を得る段階と、
(c)前記PCR産物の定量分析を通じてスフィンゴモナス属細菌由来の小胞の含量が低い場合、肝硬変、肝がん、心筋梗塞、腎不全、糖尿病、脳腫瘍、軽度認知障害、認知症、うつ病、自閉症、及びアトピー性皮膚炎からなる群から選ばれた一つ以上の疾患であると判定する段階。
(予防または改善用)によって適切に決められてもよい。一般的に、食品または飲料の製造時に、本発明の組成物は、原料に対して15重量%以下、好ましくは、10重量%以下の量で添加される。しかし、健康及び衛生を目的とするか、または健康調節を目的とする長期間の摂取の場合には、前記量は、前記範囲以下であってもよい。
細菌と細菌由来の小胞が胃腸管を通じて全身的に吸収されるかを評価するため、下記のような方法で実験を行った。まず、マウスの胃腸に蛍光で標識した前記細菌と、前記細菌由来の小胞をそれぞれ50μgの容量で口腔投与し、0分、5分、3時間、6時間、12時間後に蛍光を測定した。マウス全体のイメージを観察した結果、図1aに示すように、細菌の場合には、全身的に吸収されなかったが、細菌由来の小胞の場合には、投与後5分で全身的に吸収され、投与3時間後には、膀胱で蛍光が濃く観察され、小胞が泌尿器系に排泄されることが分かり、また、小胞は、投与12時間まで体内に存在することが分かった(図1a参照)。
細菌と細菌由来の小胞が粘膜防御膜を通過して組織に浸潤されるかを評価するため、細菌と細菌由来の小胞を腸に直接投与した後、免疫組織化学(Immunohistochemistry)方法により粘膜防御膜を通過して腸組織への浸潤を評価した。粘膜組織において細菌と小胞の存在を評価するため、細菌と小胞に対する抗体を作製してGFP(Green fluorescent protein)を付けて使用し、DAPI(4、6-diamidino 2-phenylindole)染色を行った後、顕微鏡で観察した。
血液または尿を先に10mlのチューブに入れ、遠心分離機(3,500xg、10min、4℃)で浮遊物を沈めた後、上澄み液だけを新しい10mlのチューブに移した。0.22μmのフィルターを使用して細菌及び異物を除去した後、セントリプレップチューブ(centrifugal filters 50kD)に移して1500xg、4℃で15分間遠心分離して50kDより小さな物質は捨て、10mlまで濃縮させた。再び0.22μmのフィルターを使用してバクテリア及び異物を除去した後、Type 90tiローターで150,000xg、4℃で3時間の間超高速遠心分離を行い、上澄み液を除去した後、塊状のペレットを生理食塩水(Phosphate buffered saline、PBS)で溶かした。
前記実施例3の方法で肝硬変患者97人、肝がん患者76人、さらに年齢と性別をマッチングした健常者171人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて肝硬変及び肝がん患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図3参照)。
前記実施例3の方法で心筋梗塞患者69人と、年齢と性別をマッチングした健常者159人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて心筋梗塞患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図4参照)。
前記実施例3の方法で腎不全患者36人と、年齢と性別をマッチングした健常者72人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて腎不全患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図5参照)。
前記実施例3の方法で糖尿病患者81人と、年齢と性別をマッチングした健常者126人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて糖尿病患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図6を参照)。
前記実施例3の方法で脳患者80人と、年齢と性別をマッチングした健常者121人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて脳腫瘍患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図7参照)。
前記実施例3の方法で軽度認知障害患者76人、アルツハイマー認知症患者70人、及び年齢と性別をマッチングした健常者146人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて軽度認知障害及びアルツハイマー認知症患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図8参照)。
前記実施例3の方法でうつ病患者70人と、年齢と性別をマッチングした健常者140人の血液を対象に、血液中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液に比べて、うつ病患者の血液でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図9参照)。
前記実施例3の方法で自閉症患者30人と、年齢と性別をマッチングした健常者40人の尿を対象に、尿中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の尿に比べて自閉症患者の尿中でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図10を参照)。
前記実施例3の方法でアトピー性皮膚炎患者61人と、年齢と性別をマッチングした健常者52人の血液及び尿を対象に、血液及び尿中に存在する小胞から遺伝子を抽出してメタゲノム解析を行った後、スフィンゴモナス属細菌由来の小胞の分布を評価した。その結果、健常者の血液及び尿に比べてアトピー性皮膚炎患者の血液及び尿でスフィンゴモナス属細菌由来の小胞が有意に減少していることを確認した(図11を参照)。
スフィンゴモナス・パウシモビリス及びスフィンゴモナス・コーリエンシス菌株を培養した後、その小胞を分離して特性を分析した。前記菌株を37℃培養器で吸光度(OD 600)が1.0~1.5になるまで、MRS(de Man-Rogosa and Sharpe)培地で培養した後、LB(Luria-Bertani)培地にサブカルチャーした。以後、菌株が含まれている培養液を回収して10,000xg、4℃で20分間遠心分離して菌体を除去し、0.22μmのフィルターでろ過した。ろ過した上澄み液を100 kDa Pellicon 2 Cassetteフィルターメンブレン(Merck Millipore、US)でMasterFlexポンプシステム(Cole-Parmer、US)を用いて微細ろ過(microfiltration)によって50ml以下の体積で濃縮した。濃縮させた上澄み液を再び0.22μmのフィルターでろ過した後、BCA(Bicinchoninic acid)アッセイを用いてタンパク質を定量し、得られた小胞に対して下記実験を行った。
炎症細胞においてスフィンゴモナス・パウシモビリス由来の小胞(Sphingomonas paucimobilis EV、SPC101)の炎症メディエーター(IL-6、TNF-α)の分泌に対する影響を調べるため、マウスマクロファージ細胞株であるRaw 264.7細胞にスフィンゴモナス・パウシモビリス由来の小胞を様々な濃度
(0.1、1、10μg/ml)で処理した後、細胞死滅とELISAを行った。
前記実施例14の結果に基づいて、スフィンゴモナス・パウシモビリス由来の小胞の抗炎症効果を評価するため、様々な濃度(0.1、1、10μg/ml)のスフィンゴモナス・パウシモビリス由来の小胞(SPC101)をマウスマクロファージ細胞株に12時間前処理した後、病原性原因因子である大腸菌由来の小胞1μg/mlを処理し、12時間後に炎症性サイトカインの分泌をELISAで測定した。
前記実施例16の結果に基づいて、他のスフィンゴモナス属細菌の抗炎症効果を評価するため、スフィンゴモナス・コーリエンシス由来の小胞(SPC102)を様々な濃度(0.1、1、10μg/ml)でマウスマクロファージ細胞株に12時間前処理した後、病原性原因因子である大腸菌由来の小胞1μg/mlを処理し、12時間後に炎症性サイトカインの分泌をELISAで測定した。
スフィンゴモナス・パウシモビリス由来の小胞を経口で投与したとき、時間別の臓器内の吸収及び分布を確認するため、以下のような方法で実験を行った。蛍光で標識したスフィンゴモナス・パウシモビリス由来の小胞10μgを経口で投与し、それぞれ1、3、6、32、48、72時間後に蛍光を側定した。マウス全体のイメージの蛍光を観察した結果、経口投与1時間からスフィンゴモナス・パウシモビリス由来の小胞が胃に分布し、3時間からは小腸及び大腸にも分布することを確認し、これらの臓器内の分布が72時間まで維持されることを観察した(図16参照)。
Claims (8)
- スフィンゴモナス(Sphingomonas)属細菌由来の小胞を有効成分として含む、炎症の予防または治療用薬学的組成物であって、
前記スフィンゴモナス属細菌が、スフィンゴモナス・パウシモビリス(Sphingomonas paucimobilis)又はスフィンゴモナス・コーリエンシス(Sphingomonas koreensis)から選択される、薬学的組成物。 - 前記小胞は、平均直径が10~200nmであることを特徴とする、請求項1に記載の薬学的組成物。
- 前記小胞は、前記スフィンゴモナス属細菌から自然的または人工的に分泌されることを特徴とする、請求項1又は2に記載の薬学的組成物。
- スフィンゴモナス(Sphingomonas)属細菌由来の小胞を有効成分として含む、炎症の予防または改善用食品組成物であって、
前記スフィンゴモナス属細菌が、スフィンゴモナス・パウシモビリス(Sphingomonas paucimobilis)又はスフィンゴモナス・コーリエンシス(Sphingomonas koreensis)から選択される、食品組成物。 - 前記小胞は、平均直径が10~200nmであることを特徴とする、請求項4に記載の食品組成物。
- 前記小胞は、前記スフィンゴモナス属細菌から自然的または人工的に分泌されることを特徴とする、請求項4又は5に記載の食品組成物。
- スフィンゴモナス(Sphingomonas)属細菌由来の小胞を有効成分として含む、炎症の予防または改善用化粧料組成物であって、
前記スフィンゴモナス属細菌が、スフィンゴモナス・パウシモビリス(Sphingomonas paucimobilis)又はスフィンゴモナス・コーリエンシス(Sphingomonas koreensis)から選択される、化粧料組成物。 - スフィンゴモナス(Sphingomonas)属細菌由来の小胞の、炎症の予防又は治療に用いられる薬剤を生産するための使用であって、
前記スフィンゴモナス属細菌が、スフィンゴモナス・パウシモビリス(Sphingomonas paucimobilis)又はスフィンゴモナス・コーリエンシス(Sphingomonas koreensis)から選択される、使用。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180158623 | 2018-12-10 | ||
KR10-2018-0158623 | 2018-12-10 | ||
KR10-2019-0132138 | 2019-10-23 | ||
KR1020190132138A KR102242196B1 (ko) | 2018-12-10 | 2019-10-23 | 스핀고모나스 속 세균 유래 나노소포 및 이의 용도 |
JP2021510417A JP7132661B2 (ja) | 2018-12-10 | 2019-11-20 | スフィンゴモナス属細菌由来のナノ小胞及びその用途 |
PCT/KR2019/015902 WO2020122450A1 (ko) | 2018-12-10 | 2019-11-20 | 스핀고모나스 속 세균 유래 나노소포 및 이의 용도 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021510417A Division JP7132661B2 (ja) | 2018-12-10 | 2019-11-20 | スフィンゴモナス属細菌由来のナノ小胞及びその用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022106991A JP2022106991A (ja) | 2022-07-20 |
JP7378847B2 true JP7378847B2 (ja) | 2023-11-14 |
Family
ID=71142970
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021510417A Active JP7132661B2 (ja) | 2018-12-10 | 2019-11-20 | スフィンゴモナス属細菌由来のナノ小胞及びその用途 |
JP2022078846A Active JP7378847B2 (ja) | 2018-12-10 | 2022-05-12 | スフィンゴモナス属細菌由来のナノ小胞及びその用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021510417A Active JP7132661B2 (ja) | 2018-12-10 | 2019-11-20 | スフィンゴモナス属細菌由来のナノ小胞及びその用途 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11529377B2 (ja) |
EP (1) | EP3896174A4 (ja) |
JP (2) | JP7132661B2 (ja) |
KR (1) | KR102242196B1 (ja) |
CN (1) | CN112654722A (ja) |
AU (1) | AU2019399286B2 (ja) |
BR (1) | BR112021003775A2 (ja) |
CA (1) | CA3111069A1 (ja) |
CL (1) | CL2021000414A1 (ja) |
IL (1) | IL281117A (ja) |
MX (1) | MX2021002409A (ja) |
MY (1) | MY195855A (ja) |
PH (1) | PH12021550438A1 (ja) |
SG (1) | SG11202101841QA (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102334433B1 (ko) * | 2019-07-08 | 2021-12-03 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 뇌종양 진단방법 |
JP2023554271A (ja) * | 2020-12-08 | 2023-12-27 | エムディー ヘルスケア インコーポレイテッド | スフィンゴモナス細菌由来小胞を含む神経疾患または精神疾患の予防または治療用組成物 |
KR20220095156A (ko) * | 2020-12-29 | 2022-07-06 | 한국과학기술원 | 고 당분 환경에서의 뇌종양 예방 또는 치료용 조성물 |
KR102599728B1 (ko) * | 2021-04-01 | 2023-11-08 | 주식회사 지놈앤컴퍼니 | 신규한 스핑고모나스 파우치모빌리스 균주 및 이의 용도 |
KR102361015B1 (ko) * | 2021-10-18 | 2022-02-14 | 큐티스바이오 주식회사 | 스핑고모나스 올레이의 피부 상태 개선 용도 |
FR3133312B1 (fr) * | 2022-03-08 | 2024-07-19 | Basf Beauty Care Solutions France Sas | Utilisation cosmétique ou dermatologique de Sphingomonas glacialis et/ou d’une composition la comprenant |
CN114854667B (zh) * | 2022-06-14 | 2023-08-22 | 江苏省中医药研究院(江苏省中西医结合医院) | 一种猕猴桃来源的植物纳米囊泡及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018111028A1 (ko) | 2016-12-16 | 2018-06-21 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 심장질환 진단방법 |
WO2018155950A1 (ko) | 2017-02-24 | 2018-08-30 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 당뇨병 진단 방법 |
WO2018216912A1 (ko) | 2017-05-26 | 2018-11-29 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 자폐증 진단방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10330273A (ja) * | 1997-05-30 | 1998-12-15 | Kibun Food Chemifa Co Ltd | 皮膚外用剤の製造方法 |
EP0887070B1 (en) * | 1997-05-30 | 2004-12-22 | Kibun Food ChemiFA Co., Ltd. | External composition for skin comprising sphingoglycolipid |
WO2011027971A2 (ko) * | 2009-09-01 | 2011-03-10 | 주식회사이언메딕스 | 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법 |
KR20110082480A (ko) * | 2010-01-11 | 2011-07-19 | 포항공과대학교 산학협력단 | 포유동물 체내에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도 |
WO2014039503A1 (en) * | 2012-09-04 | 2014-03-13 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
WO2016144139A2 (ko) * | 2015-03-11 | 2016-09-15 | 주식회사 엠디헬스케어 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
KR101745809B1 (ko) | 2015-12-31 | 2017-06-12 | 한국생명공학연구원 | 세포밖 소포 생성 및 숙주 면역반응을 조절하는 Small RNA 유전자 및 이의 용도 |
KR101923969B1 (ko) | 2016-07-08 | 2018-11-30 | 주식회사 엠디헬스케어 | 프로피오니박테리움 속 세균 유래 나노소포 및 이의 용도 |
KR101940423B1 (ko) | 2016-12-16 | 2019-01-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 심장질환 진단방법 |
KR101940445B1 (ko) * | 2017-02-24 | 2019-01-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 당뇨병 진단 방법 |
KR102008451B1 (ko) * | 2017-05-26 | 2019-08-07 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 자폐증 진단방법 |
KR102130485B1 (ko) | 2017-10-13 | 2020-07-06 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법 |
WO2019074216A1 (ko) * | 2017-10-13 | 2019-04-18 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 알츠하이머치매 진단방법 |
RU2727540C1 (ru) | 2019-11-22 | 2020-07-22 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Применение мембранных везикул мультипотентных стромальных клеток, индуцированных цитохалазином В, для восстановления и повышения митохондриальной функции |
-
2019
- 2019-10-23 KR KR1020190132138A patent/KR102242196B1/ko active IP Right Grant
- 2019-11-20 JP JP2021510417A patent/JP7132661B2/ja active Active
- 2019-11-20 MY MYPI2021000955A patent/MY195855A/en unknown
- 2019-11-20 MX MX2021002409A patent/MX2021002409A/es unknown
- 2019-11-20 BR BR112021003775-6A patent/BR112021003775A2/pt unknown
- 2019-11-20 CN CN201980056403.9A patent/CN112654722A/zh active Pending
- 2019-11-20 EP EP19896521.2A patent/EP3896174A4/en active Pending
- 2019-11-20 US US16/631,491 patent/US11529377B2/en active Active
- 2019-11-20 AU AU2019399286A patent/AU2019399286B2/en active Active
- 2019-11-20 SG SG11202101841QA patent/SG11202101841QA/en unknown
- 2019-11-20 CA CA3111069A patent/CA3111069A1/en active Pending
-
2021
- 2021-02-17 CL CL2021000414A patent/CL2021000414A1/es unknown
- 2021-02-25 IL IL281117A patent/IL281117A/en unknown
- 2021-02-26 PH PH12021550438A patent/PH12021550438A1/en unknown
-
2022
- 2022-05-12 JP JP2022078846A patent/JP7378847B2/ja active Active
- 2022-10-26 US US18/049,770 patent/US11944652B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018111028A1 (ko) | 2016-12-16 | 2018-06-21 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 심장질환 진단방법 |
WO2018155950A1 (ko) | 2017-02-24 | 2018-08-30 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 당뇨병 진단 방법 |
WO2018216912A1 (ko) | 2017-05-26 | 2018-11-29 | 주식회사 엠디헬스케어 | 세균 메타게놈 분석을 통한 자폐증 진단방법 |
Also Published As
Publication number | Publication date |
---|---|
PH12021550438A1 (en) | 2021-11-22 |
JP2022106991A (ja) | 2022-07-20 |
JP2021534777A (ja) | 2021-12-16 |
CA3111069A1 (en) | 2020-06-18 |
KR102242196B1 (ko) | 2021-04-20 |
EP3896174A4 (en) | 2022-08-17 |
AU2019399286B2 (en) | 2023-06-08 |
IL281117A (en) | 2021-04-29 |
KR20200070991A (ko) | 2020-06-18 |
EP3896174A1 (en) | 2021-10-20 |
BR112021003775A2 (pt) | 2021-05-25 |
MY195855A (en) | 2023-02-23 |
CN112654722A (zh) | 2021-04-13 |
MX2021002409A (es) | 2021-04-28 |
CL2021000414A1 (es) | 2021-09-20 |
US11529377B2 (en) | 2022-12-20 |
US11944652B2 (en) | 2024-04-02 |
US20220062353A1 (en) | 2022-03-03 |
SG11202101841QA (en) | 2021-03-30 |
US20230190826A1 (en) | 2023-06-22 |
AU2019399286A1 (en) | 2021-03-04 |
JP7132661B2 (ja) | 2022-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7300762B2 (ja) | ラクトバチルス属細菌由来のナノ小胞及びその用途 | |
JP7378847B2 (ja) | スフィンゴモナス属細菌由来のナノ小胞及びその用途 | |
JP7134510B2 (ja) | プロテウス属細菌由来ナノ小胞及びその用途 | |
JP7433665B2 (ja) | マイクロコッカス属細菌由来ナノ小胞及びその用途 | |
JP7433661B2 (ja) | ラクトコッカス属細菌由来のナノ小胞及びその用途 | |
JP7291424B2 (ja) | デイノコッカス属細菌由来ナノ小胞及びその用途 | |
KR102223406B1 (ko) | 코리네박테리움 속 세균 유래 나노소포 및 이의 용도 | |
JP7186470B2 (ja) | コリネバクテリウム属細菌由来のナノ小胞及びその用途 | |
JP7441534B2 (ja) | ロドコッカス属細菌由来ナノ小胞およびその用途 | |
KR102286042B1 (ko) | 데이노코커스 속 세균 유래 나노소포 및 이의 용도 | |
KR102124794B1 (ko) | 지오바실러스 속 세균 유래 나노소포 및 이의 용도 | |
KR102185982B1 (ko) | 슈도모나스 속 세균 유래 나노소포 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231005 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231025 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7378847 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |